Arrowhead Pharmaceuticals Announces closing of collaboration agreement with Amgen
23-Nov-2016 -
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the license and collaboration agreement between Arrowhead and Amgen covering the novel RNAi ARC-LPA program has closed, following early termination of the waiting period.
About ARC-LPA
ARC-LPA is designed to reduce production of ...
Amgen
cardiovascular diseases
pharmaceuticals